Business Context and Reporting Period
Company: Alumis Inc. (ALMS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune disorders. Its primary product candidate is envu (envudeucitinib), a second-generation TYK2 inhibitor for moderate-to-severe plaque psoriasis (PsO) and systemic lupus erythematosus (SLE). The company also has a CNS-penetrant molecule, A-005, in Phase 1 development. Following the May 2025 acquisition of ACELYRIN, Alumis holds the lonigutamab program for Thyroid Eye Disease (TED), though strategic alternatives are being pursued for this asset.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total Revenue | $1,662 | $2,666 | $3,403 | $20,055 |
| Net Income (Loss) | $(142,221) | $59,321 | $(235,274) | $(39,642) |
| Loss from Operations | $(148,855) | $(140,539) | $(247,264) | $(242,067) |
| Research & Development Expenses | $85,337 | $108,755 | $166,877 | $205,377 |
| General & Administrative Expenses | $23,356 | $34,450 | $41,966 | $56,745 |
| Intangible Assets Impairment Loss | $41,824 | $0 | $41,824 | $0 |
| Cash, Cash Equivalents & Marketable Securities | $502.3 million (as of June 30, 2026) | |||
| Accumulated Deficit | $1,137.2 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the six months ended June 30, 2026, decreased by 83% compared to the prior year period. This is primarily due to the recognition of $17.4 million in license revenue in Q2 2025 from the Kaken Collaboration Agreement, which was not repeated in 2026. Collaboration revenue increased slightly year-over-year for the six-month period ($3.4M vs $2.7M).
- Net Loss Expansion: The net loss for the six months ended June 30, 2026, widened significantly to $235.3 million from a loss of $39.6 million in the prior year. The prior year period included a non-recurring $187.9 million "gain on bargain purchase" from the ACELYRIN Merger, which inflated 2025 results.
- Impairment Charge: A one-time non-cash impairment loss of $41.8 million was recorded in Q2 2026 related to the acquired IPR&D intangible asset (lonigutamab) following a strategic review decision to pursue alternatives for the program.
- Operating Expense Reduction: Despite the impairment charge, total operating expenses decreased by 4% year-over-year for the six-month period. R&D expenses dropped 19% due to lower clinical trial costs following the completion of enrollment in pivotal Phase 3 trials for envu.
- Capital Raise: In January 2026, the company completed a public offering of common stock, raising net proceeds of approximately $324.4 million.
Guidance, Outlook, and Risks
- Regulatory Milestones: Management plans to submit a New Drug Application (NDA) for envu in PsO to the FDA in the fourth quarter of 2026. Topline results for the Phase 2b trial in SLE are expected in the third quarter of 2026.
- Liquidity: As of June 30, 2026, the company held $502.3 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
- Strategic Review: The company is actively pursuing strategic alternatives for the lonigutamab program (acquired via ACELYRIN), which resulted in the Q2 impairment charge.
- Risk Factors:
- Capital Needs: The company expects to incur substantial losses for the foreseeable future and will require significant additional capital to fund R&D and commercialization.
- Regulatory Uncertainty: Success depends on FDA approval of envu; clinical trial results are not guaranteed to be predictive of regulatory outcomes.
- Legal Proceedings: A securities class action lawsuit regarding the prior ACELYRIN Phase 2b trial results remains pending, with a motion to dismiss filed by defendants.
- Macroeconomic/Tariffs: Potential tariffs on pharmaceutical ingredients and global geopolitical tensions could increase costs and disrupt supply chains.
Investor Verification Checklist
- Impairment Rationale: Verify the specific strategic alternatives being pursued for the lonigutamab program and the assumptions used in the $41.8 million impairment valuation.
- NDA Timeline: Confirm the readiness of Chemistry, Manufacturing, and Controls (CMC) data and the specific timeline for the Q4 2026 NDA submission for envu.
- Cash Burn Rate: Assess the sustainability of the $502.3 million cash balance against the projected R&D spend for the envu NDA submission and potential commercialization infrastructure build-out.
- Legal Exposure: Monitor the status of the pending securities class action lawsuit (Boukadoum v. Acelyrin) and potential defense costs or settlement risks.
- Revenue Recognition: Review the remaining deferred revenue balance ($6.7 million current) and the timeline for recognizing the remaining transaction price from the Kaken Collaboration Agreement.